2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. FXR
  5. FXR Agonist

FXR Agonist

FXR Agonists (57):

Cat. No. Product Name Effect Purity
  • HY-168332
    FXR agonist 11
    		Agonist
    FXR agonist 11 (Compound 14) is an FXR agonist with an EC50 of 1.2 μM and a maximum effect of 73.7%. FXR agonist 11 can significantly increase GSH levels in the liver and is used to study drug-induced liver injury diseases.
  • HY-50108A
    (E)-GW 4064
    		Agonist
    (E)-GW 4064 is a FXR agonist.
  • HY-122338
    Fexarine
    		Agonist
    Fexarine is a potent, non-steroidal and selective agonist of farnesoid X receptor (EC50: 38 nM). Fexarine can be used for the research of diseases linked to cholesterol, bile acids.
  • HY-N11081
    Hexanorcucurbitacin D
    		Agonist
    Hexanorcucurbitacin D, a cucurbitacin, is a weak ecdysteroid receptor agonist. Hexanorcucurbitacin D can be isolated from Trichosanthes cucumeroides roots. Hexanorcucurbitacin D can be used for the research of cardiovascular disease (CVD).
  • HY-160929
    Linafexor
    		Agonist
    Linafexor (CS-0159) is an agonist for farnesoid X receptor (FXR).
  • HY-169192
    BAR-2227
    		Agonist
    BAR-2227 (compound 3a) is a FXR agonist and LIFR inhibitor. BAR-2227 can be used to study liver fibrosis and inflammation.
  • HY-N3209
    Nelumol A
    		Agonist
    Nelumol A is a farnesoid X receptor (FXR) agonist.
  • HY-135400S
    Glyco-obeticholic acid-d5
    		Agonist
    Glyco-obeticholic acid-d5 is the deuterium labeled Glyco-Obeticholic acid. Glyco-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is a farnesoid X receptor (FXR) agonist[1].
  • HY-121110
    Fexarene
    		Agonist
    Fexarene is a potent and selective nonsteroidal Farnesoid X Receptor (FXR) agonist with an EC50 of 36 nM. Fexarene can be used in studies of cholesterol and bile acid metabolism.
  • HY-168327
    LH10
    		Agonist
    LH10 is a fexaramine-based agonist for FXR with an EC50 of 0.14 μM. LH10 exhibits liver protection efficacy, ameliorates the alpha naphthylisothiocyanate (ANIT)-induced cholestasis, APAP (HY-66005)-induced acute liver injury and non-alcoholic steatohepatitis (NASH) in mouse models.
  • HY-159845
    Lecufexor
    		Agonist
    Lecufexor is a farnesoid X receptor (FXR) agonist.
  • HY-135399S
    Tauro-obeticholic acid-d5 sodium
    		Agonist
    Tauro-obeticholic acid-d5 sodium is deuterium labeled Tauro-obeticholic acid. Tauro-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is an orally bioavailable farnesoid-X receptor (FXR) agonist.
  • HY-117918
    ST-1892
    		Agonist
    ST-1892 (compound 14) is a highly potent FXR agonist (EC50=7.2 nM) that can be used to study diseases or disorders caused by metabolic inflammation.
  • HY-113567
    GSK2324
    		Agonist
    GSK2324 (Compd 1c) is a FXR agonist for diabetes study, with an EC50 of 120 nM. GSK2324 exhibits t1/2 values of 84 min (mouse), 170 min (rat), 110 min (beagle) and 120 min (cyno), respectively.
  • HY-135399A
    Tauro-obeticholic acid sodium
    		Agonist
    Tauro-obeticholic acid sodium is an active metabolite of Obeticholic acid (HY-12222). Obeticholic acid is a potent, selective and orally active FXR agonist.
  • HY-W653920
    Tauro 6-ethlchenodeoxycholic acid-d5(sodium）
    		Agonist
    Tauro 6-ethlchenodeoxycholic acid-d5(sodium） is deuterium labeled Tauro-obeticholic acid. Tauro-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is an orally bioavailable farnesoid-X receptor (FXR) agonist.
  • HY-121153
    Altenusin
    		Agonist
    Altenusin shows markedly DPPH radical scavenging activities.